Women's Health

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

FDA Extends Review Period for Elinzanetant NDA for Menopausal Vasomotor Symptoms
FDA Extends Review Period for Elinzanetant NDA for Menopausal Vasomotor Symptoms

July 25th 2025

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

FDA Grants Fast Track Designation for Sprout's Flibanserin to Treat HSDD in Postmenopausal Women / image credit ©muhammed/stock.adobe.com
FDA Grants Fast Track Designation for Sprout's Flibanserin to Treat HSDD in Postmenopausal Women

July 24th 2025

FDA Advisory Committee Urges Revised Black Box Warnings on Hormone Replacement Therapy/ image credit ©JEGAS RA/stock.adobe.com
FDA Advisory Panel Calls for Revised Class Labeling for Menopausal Hormone Replacement Therapy

July 24th 2025

Pre- and Post-Menopausal Hormone Therapy Has Differential Effect on Breast Cancer Subtypes
Pre- and Post-Menopausal Hormone Therapy Has Differential Effect on Breast Cancer Subtypes

July 17th 2025

t New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism
New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

July 16th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.